Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
$178.85
+1.3%
$176.47
$136.99
$182.38
$19.75B0.49991,650 shs436,517 shs
Elekta AB stock logo
EKTAY
Elekta
$5.19
+0.4%
$5.12
$4.36
$7.13
$1.99B1.26,808 shs3,536 shs
Guardant Health, Inc. stock logo
GH
Guardant Health
$50.25
+0.1%
$45.45
$20.14
$53.42
$6.26B1.442.17 million shs956,932 shs
Natera, Inc. stock logo
NTRA
Natera
$161.50
0.0%
$160.34
$92.14
$183.00
$22.09B1.731.43 million shs468,868 shs
Invitae Co. stock logo
NVTA
Invitae
$0.00
$0.00
$0.02
$0.02
$80K1.5923.72 million shs75 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
0.00%+0.63%+3.00%+9.00%+26.93%
Elekta AB stock logo
EKTAY
Elekta
0.00%+2.98%+0.87%+9.73%-20.15%
Guardant Health, Inc. stock logo
GH
Guardant Health
0.00%-1.20%+3.80%+23.83%+76.87%
Natera, Inc. stock logo
NTRA
Natera
0.00%-3.85%-2.42%+20.64%+44.66%
Invitae Co. stock logo
NVTA
Invitae
0.00%0.00%0.00%0.00%-57.14%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
4.9386 of 5 stars
2.34.04.24.72.92.52.5
Elekta AB stock logo
EKTAY
Elekta
3.2881 of 5 stars
0.05.01.70.02.31.71.9
Guardant Health, Inc. stock logo
GH
Guardant Health
3.8504 of 5 stars
2.51.00.04.43.82.50.6
Natera, Inc. stock logo
NTRA
Natera
2.1396 of 5 stars
2.52.00.00.03.42.50.6
Invitae Co. stock logo
NVTA
Invitae
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
2.69
Moderate Buy$185.733.85% Upside
Elekta AB stock logo
EKTAY
Elekta
2.00
HoldN/AN/A
Guardant Health, Inc. stock logo
GH
Guardant Health
3.00
Buy$53.766.99% Upside
Natera, Inc. stock logo
NTRA
Natera
3.00
Buy$184.6314.32% Upside
Invitae Co. stock logo
NVTA
Invitae
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest GH, EKTAY, NTRA, NVTA, and DGX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/13/2025
Guardant Health, Inc. stock logo
GH
Guardant Health
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$60.00 ➝ $65.00
6/3/2025
Elekta AB stock logo
EKTAY
Elekta
Danske
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeHold
5/15/2025
Natera, Inc. stock logo
NTRA
Natera
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$205.00 ➝ $210.00
5/9/2025
Natera, Inc. stock logo
NTRA
Natera
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$211.00 ➝ $218.00
5/9/2025
Natera, Inc. stock logo
NTRA
Natera
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$160.00 ➝ $190.00
5/6/2025
Guardant Health, Inc. stock logo
GH
Guardant Health
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$50.00 ➝ $60.00
5/6/2025
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$180.00 ➝ $190.00
5/5/2025
Guardant Health, Inc. stock logo
GH
Guardant Health
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
5/5/2025
Guardant Health, Inc. stock logo
GH
Guardant Health
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$52.00 ➝ $57.00
5/1/2025
Guardant Health, Inc. stock logo
GH
Guardant Health
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$60.00 ➝ $65.00
5/1/2025
Guardant Health, Inc. stock logo
GH
Guardant Health
TD Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$56.00 ➝ $60.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
$9.87B2.02$13.65 per share13.10$61.38 per share2.91
Elekta AB stock logo
EKTAY
Elekta
$1.71B1.17$0.61 per share8.48$2.19 per share2.37
Guardant Health, Inc. stock logo
GH
Guardant Health
$739.02M8.42N/AN/A($1.13) per share-44.47
Natera, Inc. stock logo
NTRA
Natera
$1.70B13.00N/AN/A$9.05 per share17.85
Invitae Co. stock logo
NVTA
Invitae
$481.58M0.00N/AN/A$0.42 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
$871M$7.9122.6117.052.478.81%15.11%6.65%7/22/2025 (Estimated)
Elekta AB stock logo
EKTAY
Elekta
$22.37M$0.05103.8212.07N/A1.15%11.55%3.75%8/27/2025 (Estimated)
Guardant Health, Inc. stock logo
GH
Guardant Health
-$436.37M-$3.39N/AN/AN/A-53.82%N/A-26.77%8/6/2025 (Estimated)
Natera, Inc. stock logo
NTRA
Natera
-$190.43M-$1.47N/AN/AN/A-10.36%-18.29%-11.68%8/14/2025 (Estimated)
Invitae Co. stock logo
NVTA
Invitae
-$3.11B-$5.38N/AN/AN/A-299.14%-6,100.71%-19.68%N/A

Latest GH, EKTAY, NTRA, NVTA, and DGX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/22/2025Q2 2025
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
$2.56N/AN/AN/A$2.73 billionN/A
5/28/2025Q4 2025
Elekta AB stock logo
EKTAY
Elekta
$0.13$0.11-$0.02-$0.10$507.19 million$503.22 million
5/8/2025Q1 2025
Natera, Inc. stock logo
NTRA
Natera
-$0.59-$0.50+$0.09-$0.50$446.68 million$501.83 million
4/30/2025Q1 2025
Guardant Health, Inc. stock logo
GH
Guardant Health
-$0.57-$0.49+$0.08-$0.77$189.91 million$203.47 million
4/22/2025Q1 2025
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
$2.15$2.21+$0.06$1.94$2.63 billion$2.65 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
$3.201.79%N/A40.46%14 Years
Elekta AB stock logo
EKTAY
Elekta
$0.122.31%N/A240.00%N/A
Guardant Health, Inc. stock logo
GH
Guardant Health
N/AN/AN/AN/AN/A
Natera, Inc. stock logo
NTRA
Natera
N/AN/AN/AN/AN/A
Invitae Co. stock logo
NVTA
Invitae
N/AN/AN/AN/AN/A

Latest GH, EKTAY, NTRA, NVTA, and DGX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/14/2025
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
quarterly$0.801.86%7/7/20257/7/20257/21/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
0.84
1.44
1.31
Elekta AB stock logo
EKTAY
Elekta
0.70
1.09
0.86
Guardant Health, Inc. stock logo
GH
Guardant Health
N/A
4.11
3.76
Natera, Inc. stock logo
NTRA
Natera
N/A
3.87
3.74
Invitae Co. stock logo
NVTA
Invitae
N/A
2.39
2.25

Institutional Ownership

CompanyInstitutional Ownership
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
88.06%
Elekta AB stock logo
EKTAY
Elekta
N/A
Guardant Health, Inc. stock logo
GH
Guardant Health
92.60%
Natera, Inc. stock logo
NTRA
Natera
99.90%
Invitae Co. stock logo
NVTA
Invitae
61.28%

Insider Ownership

CompanyInsider Ownership
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
8.16%
Elekta AB stock logo
EKTAY
Elekta
41.28%
Guardant Health, Inc. stock logo
GH
Guardant Health
6.10%
Natera, Inc. stock logo
NTRA
Natera
7.60%
Invitae Co. stock logo
NVTA
Invitae
0.74%
CompanyEmployeesShares OutstandingFree FloatOptionable
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
56,000111.64 million102.53 millionOptionable
Elekta AB stock logo
EKTAY
Elekta
4,718383.57 million225.23 millionNot Optionable
Guardant Health, Inc. stock logo
GH
Guardant Health
2,021123.89 million116.33 millionNot Optionable
Natera, Inc. stock logo
NTRA
Natera
4,434136.55 million126.17 millionOptionable
Invitae Co. stock logo
NVTA
Invitae
1,700267.01 million284.37 millionOptionable

Recent News About These Companies

LabCorp On the Verge of Acquiring Invitae’s Assets
Kirkland Defends Invitae Representation Amid Conflict Claims
Labcorp to acquire Invitae assets for $239 million
Labcorp wins $239M bid for bankrupt Invitae
Labcorp to Buy Assets of Bankrupt Invitae for $239M

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Quest Diagnostics stock logo

Quest Diagnostics NYSE:DGX

$178.85 +2.25 (+1.27%)
Closing price 07/3/2025 03:56 PM Eastern
Extended Trading
$177.79 -1.06 (-0.59%)
As of 07/3/2025 04:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Elekta stock logo

Elekta OTCMKTS:EKTAY

$5.19 +0.02 (+0.39%)
As of 07/3/2025 12:57 PM Eastern

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care. In addition, the company offers stereotactic radiosurgery, such as Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Elekta Esprit. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.

Guardant Health stock logo

Guardant Health NASDAQ:GH

$50.25 +0.07 (+0.14%)
Closing price 07/3/2025 02:58 PM Eastern
Extended Trading
$50.50 +0.25 (+0.50%)
As of 07/3/2025 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Natera stock logo

Natera NASDAQ:NTRA

$161.50 -0.07 (-0.04%)
Closing price 07/3/2025 03:54 PM Eastern
Extended Trading
$161.50 0.00 (0.00%)
As of 07/3/2025 04:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Invitae stock logo

Invitae NYSE:NVTA

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.